Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Agomelatine: an agent against anhedonia and abulia?

Thome J, Foley P.

J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S3-7. doi: 10.1007/s00702-013-1126-6. Epub 2013 Dec 6. Review.

PMID:
24311062
2.

Agomelatine in the treatment of mood and anxiety disorders.

Baldwin DS, Lopes AT.

Br J Hosp Med (Lond). 2010 Mar;71(3):153-6.

PMID:
20220721
3.

Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study.

Martinotti G, Sepede G, Gambi F, Di Iorio G, De Berardis D, Di Nicola M, Onofrj M, Janiri L, Di Giannantonio M.

J Clin Psychopharmacol. 2012 Aug;32(4):487-91. doi: 10.1097/JCP.0b013e31825d6c25.

PMID:
22722509
4.

Agomelatine-induced hepatotoxicity.

Štuhec M.

Wien Klin Wochenschr. 2013 Apr;125(7-8):225-6. doi: 10.1007/s00508-013-0344-0. Epub 2013 Mar 22. No abstract available.

PMID:
23519541
5.

[Development of a new antidepressant : agomelatine].

Mocaër E, Delalleau B, Boyer PA, de Bodinat C.

Med Sci (Paris). 2005 Oct;21(10):888-93. Review. French.

6.

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.

Kasper S, Hamon M.

World J Biol Psychiatry. 2009;10(2):117-26. doi: 10.1080/15622970902717024. Review.

PMID:
19255935
7.

Major depressive disorder, anhedonia and agomelatine: an open-label study.

Di Giannantonio M, Di Iorio G, Guglielmo R, De Berardis D, Conti CM, Acciavatti T, Cornelio M, Martinotti G.

J Biol Regul Homeost Agents. 2011 Jan-Mar;25(1):109-14.

PMID:
21382280
8.

Diazepam discontinuation through agomelatine in schizophrenia with insomnia and depression.

Morera-Fumero AL, Abreu-Gonzalez P.

J Clin Psychopharmacol. 2010 Dec;30(6):739-41. doi: 10.1097/JCP.0b013e3181fbbb7d. No abstract available.

PMID:
21057240
9.

[Agomelatine].

Tessmer M.

Med Monatsschr Pharm. 2009 Aug;32(8):282-8. Review. German.

PMID:
19777735
10.

Agomelatine: a novel atypical antidepressant.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2007 Dec;45(12):13-7.

PMID:
18246859
11.

Anhedonia and major depression: the role of agomelatine.

Di Giannantonio M, Martinotti G.

Eur Neuropsychopharmacol. 2012;22 Suppl 3:S505-10. Review.

PMID:
22959116
12.

[Agomelatine: the first "melatoninergic" antidepressant].

Bánki MC.

Neuropsychopharmacol Hung. 2006 Oct;8(3):105-12. Review. Hungarian.

PMID:
17211046
13.

Agomelatine: new drug. Adverse effects and no proven efficacy.

[No authors listed]

Prescrire Int. 2009 Dec;18(104):241-5.

PMID:
20020562
14.

Consequences of long-term treatment with agomelatine on depressive-like behavior and neurobiological abnormalities in pinealectomized rats.

Tchekalarova J, Nenchovska Z, Atanasova D, Atanasova M, Kortenska L, Stefanova M, Alova L, Lazarov N.

Behav Brain Res. 2016 Apr 1;302:11-28. doi: 10.1016/j.bbr.2015.12.043. Epub 2016 Jan 11.

PMID:
26779670
15.

Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.

Stein DJ, Ahokas AA, de Bodinat C.

J Clin Psychopharmacol. 2008 Oct;28(5):561-6. doi: 10.1097/JCP.0b013e318184ff5b.

PMID:
18794654
16.

Agomelatine: a preliminary review of a new antidepressant.

Zupancic M, Guilleminault C.

CNS Drugs. 2006;20(12):981-92. Review.

PMID:
17140278
17.

[Clinical and therapeutic perspectives of agomelatine (valdoxan) in the treatment of anhedonia in patients with endogenous depressions].

Panteleeva GP, Abramova LI, Oleichik IV, Omelchenko MA, Subbotskaya NV, Sorokin SA, Novozhenova TE, Nikiforova IY.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(11):47-54. doi: 10.17116/jnevro201511511147-54. Russian.

PMID:
26978051
18.

Agomelatine treatment with adolescents with ADHD.

Niederhofer H.

J Atten Disord. 2012 Aug;16(6):530-2. doi: 10.1177/1087054711423631. Epub 2012 Jun 5.

PMID:
22668524
19.

Could agomelatine be the ideal antidepressant?

Pandi-Perumal SR, Srinivasan V, Cardinali DP, Monti MJ.

Expert Rev Neurother. 2006 Nov;6(11):1595-608. Review.

PMID:
17144776
20.

Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats.

Mairesse J, Silletti V, Laloux C, Zuena AR, Giovine A, Consolazione M, van Camp G, Malagodi M, Gaetani S, Cianci S, Catalani A, Mennuni G, Mazzetta A, van Reeth O, Gabriel C, Mocaër E, Nicoletti F, Morley-Fletcher S, Maccari S.

Int J Neuropsychopharmacol. 2013 Mar;16(2):323-38. doi: 10.1017/S1461145711001970. Epub 2012 Feb 6.

PMID:
22310059

Supplemental Content

Support Center